activins and Myelodysplastic Syndromes

activins has been researched along with Myelodysplastic Syndromes in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Usuki, K	1
Attie, KM; Chromik, J; Germing, U; Giagounidis, A; Götze, KS; Kiewe, P; Laadem, A; Mayer, K; Platzbecker, U; Radsak, M; Sherman, ML; Wolff, T; Zhang, X	1
Fenaux, P; Kiladjian, JJ; Platzbecker, U	1
Hermine, O; Mies, A; Platzbecker, U	1

Reviews

2 review(s) available for activins and Myelodysplastic Syndromes

Article	Year
Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Blood, 2019, 02-21, Volume: 133, Issue:8 Topics: Activin Receptors, Type II; Activins; Anemia; Bone Morphogenetic Proteins; Disease-Free Survival; Erythrocyte Transfusion; Growth Differentiation Factors; Humans; Immunoglobulin Fc Fragments; Iron Overload; Myelodysplastic Syndromes; Recombinant Fusion Proteins; Survival Rate	2019
Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts. Current hematologic malignancy reports, 2016, Volume: 11, Issue:6 Topics: Activin Receptors, Type II; Activins; Humans; Immunoglobulin Fc Fragments; Iron Overload; Myelodysplastic Syndromes; Phosphoproteins; Recombinant Fusion Proteins; RNA Splicing Factors; Transforming Growth Factor beta	2016

Article

Year

Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis.

Blood, 2019, 02-21, Volume: 133, Issue:8

Topics: Activin Receptors, Type II; Activins; Anemia; Bone Morphogenetic Proteins; Disease-Free Survival; Erythrocyte Transfusion; Growth Differentiation Factors; Humans; Immunoglobulin Fc Fragments; Iron Overload; Myelodysplastic Syndromes; Recombinant Fusion Proteins; Survival Rate

2019

Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts.

Current hematologic malignancy reports, 2016, Volume: 11, Issue:6

Topics: Activin Receptors, Type II; Activins; Humans; Immunoglobulin Fc Fragments; Iron Overload; Myelodysplastic Syndromes; Phosphoproteins; Recombinant Fusion Proteins; RNA Splicing Factors; Transforming Growth Factor beta

2016

Trials

1 trial(s) available for activins and Myelodysplastic Syndromes

Article	Year
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. The Lancet. Oncology, 2017, Volume: 18, Issue:10 Topics: Activin Receptors, Type II; Activins; Adult; Aged; Anemia; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Germany; Humans; Immunoglobulin Fc Fragments; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Prospective Studies; Recombinant Fusion Proteins; Risk Assessment; Severity of Illness Index; Survival Analysis; Time Factors; Treatment Outcome	2017

Article

Year

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.

The Lancet. Oncology, 2017, Volume: 18, Issue:10

Topics: Activin Receptors, Type II; Activins; Adult; Aged; Anemia; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Germany; Humans; Immunoglobulin Fc Fragments; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Prospective Studies; Recombinant Fusion Proteins; Risk Assessment; Severity of Illness Index; Survival Analysis; Time Factors; Treatment Outcome

2017

Other Studies

1 other study(ies) available for activins and Myelodysplastic Syndromes

Article	Year
[New treatment for myelodysplastic syndromes: luspatercept and oral hypomethylating agents]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2022, Volume: 63, Issue:9 Topics: Activin Receptors, Type II; Activins; Azacitidine; Cytidine Deaminase; Decitabine; Humans; Immunoglobulin Fc Fragments; Ligands; Myelodysplastic Syndromes; Recombinant Fusion Proteins; Treatment Outcome	2022